Manager TitleAgeSince
President 63 2010-05-26
Director TitleAgeSince
Director/Board Member 63 2010-03-25
Director/Board Member 85 2011-05-31
Director/Board Member 79 2013-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
+4.16%+4.16%+49.37%+94.17% 74.68B
-12.74%-12.90%+6.66%+56.96% 58.7B
-1.63%+1.39%+4.33%+32.49% 48.36B
-4.62%-4.24%+312.29%+674.07% 43.05B
-0.68%-1.29%+28.30%+28.98% 42.48B
-4.18%-1.89%+0.26%+103.72% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-1.54%-3.46%-12.03%-14.47% 23.93B
-2.26%-8.91%-38.87%+303.59% 22.22B
Average -2.44%-2.18%+39.94%+148.02% 42.9B
Weighted average by Cap. -2.66%-1.56%+46.83%+141.26%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-